Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Design Therapeutics Inc (NQ: DSGN )

3.350 +0.120 (+3.72%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 167,072
Open 3.250
Bid (Size) 3.350 (10)
Ask (Size) 3.620 (1)
Prev. Close 3.230
Today's Range 3.210 - 3.380
52wk Range 1.940 - 8.310
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
The 100%+ Club: Piper Sandler’s 3 Top Picks for Triple-Digit Gains
Biotechs can see triple-digit returns or dramatic losses but these Piper Sandler stocks have the potential to achieve them. 
Via InvestorPlace
DSGN Stock Earnings: Design Therapeutics Beats EPS for Q1 2024
DSGN stock results show that Design Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace

Performance

YTD
+31.89%
+31.89%
1 Month
-20.43%
-20.43%
3 Month
-16.87%
-16.87%
6 Month
+21.38%
+21.38%
1 Year
-44.72%
-44.72%

More News

Read More
Design Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program Milestones
From Design Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Design Therapeutics to Participate in the 2024 RBC Capital Markets Global Healthcare Conference
From Design Therapeutics, Inc.
Via GlobeNewswire
Earnings Preview For Design Therapeutics
Via Benzinga
Design Therapeutics And 2 Other Stocks Under $5 Insiders Are Buying
Via Benzinga
Topics Stocks
Exposures US Equities
DSGN Stock Earnings: Design Therapeutics Beats EPS for Q4 2023
Via InvestorPlace
Design Therapeutics Outlines Progress Across GeneTAC™ Platform and Announces Fourth Quarter and Full Year 2023 Financial Results
From Design Therapeutics, Inc.
Via GlobeNewswire
Earnings Scheduled For March 19, 2024
Via Benzinga
Design Therapeutics to Webcast Fourth Quarter and Full Year 2023 Financial Results and Comprehensive Portfolio Update
From Design Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Design Therapeutics Reports Third Quarter 2023 Financial Results and Plans for a Comprehensive Portfolio Update in Early 2024
From Design Therapeutics, Inc.
Via GlobeNewswire
Over $5M Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying
Via Benzinga
Topics Stocks
Exposures US Equities
Market Sentiment Teeters As US Indices, Including S&P 500, Break Key Supports: Next Levels To Watch
Via Benzinga
Topics Stocks
Exposures US Equities
Design Therapeutics' Modified DT-216 May Have Potential, But Analyst Awaits Further Developments
Via Benzinga
Nasdaq Falls 100 Points; Siyata Mobile Shares Spike Higher
Via Benzinga
Topics Stocks
Exposures US Equities
Why Shares of Design Therapeutics Are Plummeting on Tuesday
Via The Motley Fool
Why PhenomeX Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Crude Oil Down 2%; Home Depot Posts Upbeat Earnings
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Benzinga's Top Ratings Upgrades, Downgrades For August 15, 2023
Via Benzinga
Dow Falls Over 200 Points; US Retail Sales Top Expectations
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Why Is Design Therapeutics Stock Moving Lower Today?
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.